Home » Stocks » Grifols S.A.

Grifols S.A. (GRFS)

Stock Price: $18.65 USD -0.33 (-1.74%)
Updated Aug 5, 2020 4:00 PM EDT - Market closed
After-hours: $19.00 +0.35 (1.88%) Aug 5, 5:54 PM

Stock Price Chart

Key Info

Market Cap 4.81B
Revenue (ttm) 5.73B
Net Income (ttm) 702.41M
Shares Out 684.14M
EPS (ttm) 0.60
PE Ratio 31.08
Forward PE 14.04
Dividend $0.44
Dividend Yield 2.36%

Stock Quote

Trading Day Aug 5, 2020
Last Price $18.65
Previous Close $18.98
Change ($) -0.33
Change (%) -1.74%
Day's Open 19.01
Day's Range 18.61 - 19.04
Day's Volume 1,343,027
52-Week Range 13.40 - 25.73

More Stats

Market Cap 4.81B
Enterprise Value 10.14B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 684.14M
Float 1.10B
EPS (basic) n/a
EPS (diluted) 0.60
FCF / Share -0.25
Dividend $0.44
Dividend Yield 2.36%
Earnings Yield 3.22%
FCF Yield n/a
Payout Ratio 51.30%
Shares Short 2.66M
Short Ratio 2.04
Short % of Float n/a
Beta 0.36
PE Ratio 31.08
Forward PE 14.04
P/FCF Ratio n/a
PS Ratio 0.84
PB Ratio 2.04
Revenue 5.73B
Operating Income 1.26B
Net Income 702.41M
Free Cash Flow -169.72M
Net Cash -5.32B
Net Cash / Share -20.63
Gross Margin 45.92%
Operating Margin 22.01%
Profit Margin 12.30%
FCF Margin -2.96%
ROA 4.29%
ROE 10.33%
ROIC 9.60%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$38.64*
Low
38.6
Current: $18.65
High
38.6
Target: 38.64
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue5,0994,4874,3184,0503,9353,3552,7422,6211,796991
Revenue Growth13.64%3.91%6.62%2.93%17.26%22.38%4.61%45.96%81.24%-
Gross Profit2,3412,0502,1521,9121,9311,6991,4181,330827461
Operating Income1,1229941,003939970858736660279210
Net Income62559766354553247034625750.31116
Shares Outstanding688688688688688688653653653653
Earnings Per Share0.910.870.970.800.780.690.510.380.080.23
EPS Growth4.6%-10.31%21.25%2.56%13.04%35.29%36%368.75%-64.44%-
Dividend Per Share0.530.480.380.350.710.530.271.170.52-
Dividend Growth9.6%27.73%7.14%-50.84%33.33%97.05%-76.76%125.1%--
Operating Cash Flow569737842553743979592507220104
Capital Expenditures-720-539-574-540-1,075-509-295-232-137-186
Free Cash Flow-15119826813.60-33347029727583.40-82.04
Cash & Equivalents2,4711,0888978981,1441,080710474357253
Total Debt7,2096,3846,0624,9374,8614,3522,8142,8893,111887
Net Cash / Debt-4,738-5,296-5,165-4,039-3,717-3,273-2,104-2,415-2,753-634
Assets15,54312,47710,92010,1309,6028,4505,8415,6275,6401,889
Liabilities8,6977,7807,2866,4026,3005,7873,7343,7473,9751,182
Book Value4,8224,2263,6293,7213,2962,6582,1011,8771,663693
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Grifols S.A.
Country Spain
Employees 24,162
CEO Raimon Grifols Roura / Victor Grifols Deu

Stock Information

Ticker Symbol GRFS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: GRFS
IPO Date May 17, 2006

Description

Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.